Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4SCAR-PSMA T Cell Therapy in PSMA Positive Malignancies
NCT04429451Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Dec 2026
- Primary completion
- Dec 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of 4SCAR-PSMA T cells, sponsored by Shenzhen Geno-Immune Medical Institute. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
4SCAR-PSMA T cells
Beyond the preview
Go deeper on NCT04429451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04429451.